Lantern Pharma Raises Capital and Plans AI Spinout Around Zeta Platform

May 14, 2026

Lantern Pharma (NASDAQ: LTRN) has announced a registered direct offering involving the sale of approximately 2.1 million shares of common stock, alongside a concurrent private placement of warrants. The financing is intended to support the company’s continued development of its AI-driven precision oncology pipeline.

The company also revealed plans to create an independent business entity centered around its Zeta AI platform, including related technologies and personnel. The move highlights Lantern’s strategy to expand the commercial potential of its artificial intelligence and machine learning capabilities beyond traditional drug development.

#LanternPharma
#LTRN
#ArtificialIntelligence
#AI
#Biotech
#Oncology
#PrecisionMedicine
#MachineLearning
#CancerResearch
#ClinicalTrials
#DrugDevelopment
#HealthcareInnovation
#StockMarket
#JaneKing
#NewsOut